Q1 EPS Estimate for Edwards Lifesciences Cut by Analyst

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Research analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences in a report released on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $0.58 per share for the quarter, down from their previous forecast of $0.59. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.57 per share. Zacks Research also issued estimates for Edwards Lifesciences' Q2 2025 earnings at $0.61 EPS, FY2025 earnings at $2.42 EPS, Q1 2026 earnings at $0.66 EPS, Q2 2026 earnings at $0.69 EPS and FY2026 earnings at $2.78 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.57 billion. During the same period in the prior year, the firm posted $0.59 earnings per share. The firm's quarterly revenue was up 8.9% on a year-over-year basis.

EW has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft decreased their price target on Edwards Lifesciences from $103.00 to $85.00 and set a "buy" rating on the stock in a research note on Thursday, July 25th. UBS Group cut their price objective on Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating on the stock in a research report on Tuesday, September 10th. Wolfe Research raised Edwards Lifesciences from an "underperform" rating to a "peer perform" rating in a research report on Monday, July 29th. Bank of America lowered Edwards Lifesciences from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Finally, Wells Fargo & Company cut their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $75.67.

Edwards Lifesciences Trading Up 0.1 %

EW traded up $0.10 during trading hours on Friday, reaching $70.48. The company's stock had a trading volume of 2,602,374 shares, compared to its average volume of 4,640,770. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a market cap of $41.57 billion, a PE ratio of 10.18, a P/E/G ratio of 3.95 and a beta of 1.12. The business's 50-day moving average is $67.66 and its 200-day moving average is $75.83. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. This represents a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,000 shares of company stock worth $2,657,000. Company insiders own 1.29% of the company's stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the company. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences in the first quarter valued at about $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences in the second quarter valued at about $29,000. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the third quarter valued at about $32,000. Finally, Avior Wealth Management LLC increased its holdings in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after buying an additional 308 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.